H
Hepalys Pharma is a late-stage biopharmaceutical company focused on developing innovative therapeutics for liver disease in Japanese and Asian patients. The company is advancing Lanifibranor, a pan-PPAR therapeutic agent, through global Phase 3 clinical trials for Metabolic dysfunction-associated steatohepatitis (MASH). Hepalys aims to address the significant unmet medical need in non-viral liver diseases prevalent across the region.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Hepalys Pharma is a late-stage biopharmaceutical company focused on developing innovative therapeutics for liver disease in Japanese and Asian patients. The company is advancing Lanifibranor, a pan-PPAR therapeutic agent, through global Phase 3 clinical trials for Metabolic dysfunction-associated steatohepatitis (MASH). Hepalys aims to address the significant unmet medical need in non-viral liver diseases prevalent across the region.